Celcuity Inc. (CELC)Healthcare | Biotechnology | Minneapolis, United States | NasdaqCM
63.19 USD
-2.66
(-4.039%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 63.19 |
Hot Take ↕ | Oct. 10, 2026, 7:05 a.m. EDT
The investment case here is fractured by a stark disconnect between the company's operational milestones and its financial reality. On one hand, the business is hitting major targets: FDA approvals and positive trial data for breast cancer treatments, which has driven the stock up nearly 260% over the last eight years. This validates the core thesis that the technology works. However, the balance sheet tells a different story; the company is burning cash aggressively with negative free cash flow and negative book value, relying entirely on capital markets to stay alive. The market seems to be pricing in a 'boom or bust' scenario rather than sustainable growth. The options data confirms this anxiety, with traders stacking up downside insurance while only a few are betting on a moonshot recovery. Until the company demonstrates a path to profitability or significant revenue generation beyond grants, the risk of permanent capital loss remains high despite the promising science. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.065882 |
| AutoETS | 0.073470 |
| AutoARIMA | 0.073474 |
| AutoTheta | 0.130306 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.332 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 3,092,007,168 |
| Forward P/E | -789.88 |
| Beta | 0.11 |
| Website | https://www.celcuity.com |
As of Oct. 10, 2026, 7:05 a.m. EDT: Speculators are positioning heavily for downside protection with massive open interest in out-of-the-money puts (strikes 40, 50, 65, 80) compared to negligible call volume. While there is some call activity at strikes 110-165 suggesting a speculative 'lottery ticket' bet on a clinical breakthrough, the overwhelming capital deployment is in put writing and buying, indicating a fear of further decline or a belief that the current rally is a trap.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.42532468 |
| Address1 | 2,800 Campus Drive |
| Address2 | Suite 140 |
| All Time High | 151.02 |
| All Time Low | 4.03 |
| Ask | 81.45 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,765,130 |
| Average Daily Volume3 Month | 1,242,240 |
| Average Volume | 1,242,240 |
| Average Volume10Days | 1,765,130 |
| Beta | 0.108 |
| Bid | 46.9 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -0.261 |
| City | Minneapolis |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 63.19 |
| Current Ratio | 8.931 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 65.69 |
| Day Low | 62.86 |
| Display Name | Celcuity |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,653,000 |
| Earnings Call Timestamp Start | 1,786,653,000 |
| Earnings Timestamp | 1,786,651,200 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -208,479,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -15.457 |
| Enterprise Value | 3,222,507,264 |
| Eps Current Year | -4.39 |
| Eps Forward | -0.08 |
| Eps Trailing Twelve Months | -4.31 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 85.4158 |
| Fifty Day Average Change | -22.225803 |
| Fifty Day Average Change Percent | -0.26020718 |
| Fifty Two Week Change Percent | 42.532467 |
| Fifty Two Week High | 151.02 |
| Fifty Two Week High Change | -87.83 |
| Fifty Two Week High Change Percent | -0.5815786 |
| Fifty Two Week Low | 45.03 |
| Fifty Two Week Low Change | 18.16 |
| Fifty Two Week Low Change Percent | 0.4032867 |
| Fifty Two Week Range | 45.03 - 151.02 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 29,716,837 |
| Forward Eps | -0.08 |
| Forward P E | -789.875 |
| Free Cashflow | -72,001,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 155 |
| Fullday Change | -2.6599998 |
| Fullday Change Percent | -4.0394835 |
| Fullday Price | 63.19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10232 |
| Held Percent Institutions | 1.1009899 |
| Implied Shares Outstanding | 48,931,908 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota. |
| Long Name | Celcuity Inc. |
| Market | us_market |
| Market Cap | 3,092,007,168 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_254573983 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -226,482,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,914,063,320 |
| Number Of Analyst Opinions | 11 |
| Open | 65.18 |
| Operating Cashflow | -191,706,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | (763) 392-0123 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 63.19 |
| Post Market Time | 1,791,926,891 |
| Previous Close | 65.85 |
| Price Eps Current Year | -14.394077 |
| Price Hint | 2 |
| Price To Book | -242.10727 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.68 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -2.6599998 |
| Regular Market Change Percent | -4.0394835 |
| Regular Market Day High | 65.69 |
| Regular Market Day Low | 62.86 |
| Regular Market Day Range | 62.86 - 65.69 |
| Regular Market Open | 65.18 |
| Regular Market Previous Close | 65.85 |
| Regular Market Price | 63.19 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,459,284 |
| Return On Assets | -0.2578 |
| Return On Equity | -14.33703 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 48,931,908 |
| Shares Percent Shares Out | 0.2244 |
| Shares Short | 10,979,648 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,688,163 |
| Short Name | Celcuity Inc. |
| Short Percent Of Float | 0.3366 |
| Short Ratio | 11.35 |
| Source Interval | 15 |
| State | MN |
| Symbol | CELC |
| Target High Price | 177.0 |
| Target Low Price | 130.0 |
| Target Mean Price | 156.90909 |
| Target Median Price | 157.0 |
| Total Cash | 754,044,032 |
| Total Cash Per Share | 15.41 |
| Total Debt | 754,385,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 103.47435 |
| Two Hundred Day Average Change | -40.28435 |
| Two Hundred Day Average Change Percent | -0.38931727 |
| Type Disp | Equity |
| Volume | 1,459,284 |
| Website | https://www.celcuity.com |
| Zip | 55,441 |